SR 142948A is a novel non-peptide Neurotensin receptor antagonist used in scientific research. SR 142948A is a potent neurotensin receptor antagonist that affects the expression of c-Fos and has properties of antipsychotic agent. It blocks hypothermia and analgesia induced by neurotensin. It blocks the increase in the concentration of Ca+2 induced by the activation of phospholipase C in CHO cell model. SR-142948 has been used to study the role of neurotensin in the regulation of dopamine receptor activity and glutamate signalling in the brain, and in animal studies SR-142948 blocked the effects of stimulant drugs, including MDMA.
Physicochemical Properties
| Molecular Formula | C39H51N5O6 |
| Molecular Weight | 685.8522 |
| Exact Mass | 685.384 |
| CAS # | 184162-64-9 |
| Related CAS # | SR 142948 dihydrochloride |
| PubChem CID | 5311451 |
| Appearance | White to off-white solid powder |
| Density | 1.29g/cm3 |
| Boiling Point | 824.7ºC at 760 mmHg |
| Flash Point | 452.5ºC |
| Vapour Pressure | 8.51E-29mmHg at 25°C |
| Index of Refraction | 1.636 |
| LogP | 6.287 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 13 |
| Heavy Atom Count | 50 |
| Complexity | 1170 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | LWULHXVBLMWCHO-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C39H51N5O6/c1-23(2)29-21-26(37(46)43(5)15-9-14-42(3)4)12-13-31(29)44-32(35-33(49-6)10-8-11-34(35)50-7)22-30(41-44)36(45)40-39(38(47)48)27-17-24-16-25(19-27)20-28(39)18-24/h8,10-13,21-25,27-28H,9,14-20H2,1-7H3,(H,40,45)(H,47,48) |
| Chemical Name | 2-[[5-(2,6-Dimethoxyphenyl)-1-[4-[3-(dimethylamino)propyl-methylcarbamoyl]-2-propan-2-ylphenyl]pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid |
| Synonyms | SR142948A; SR-142948A; SR 142948A; SR-142948-A; SR 142948 A; 2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methylcarbamoyl)-2-isopropylphenyl)-1H-pyrazole3-carbonyl]amino] adamantane-2-carboxylic acid hydrochloride, SR 142948 hydrochloride |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In CHO-hNT1-R cells, SR 142948 (1 µM; 90 minutes) suppresses the expression of c-fos and krox24 [1]. By preventing the binding of [125I-Tyr3]NT to h-NTR1-CHO and HT 29 cell membranes, SR 142948 (0-1 µM; 1) demonstrates strong anti-clamp activity [2]. Its IC50 values are 1.19 and 0.32 nM, respectively. The depletion of anti-h-NTR1-CHO is clamped by SR 142948 (0-1 µM; 30 min) concentration and the intracellular calcium stimulation of single anti-h-NTR1-CHO cells is stimulated by SR 142948 (1, 10 nM; 60-80 sec)[2]. |
| ln Vivo | SR 142948 (0.01, 0.03, 0.3 mg/kg; i.p.; single dose) partially but significantly blocked NT conduction in hyposomnia (impedance) at doses SR 142948 (90-10 mg/kg; facial; single dose) 2 mg) in an induced manner that prevents the enhanced ACh release produced by NT (100 nM) [2]. SR 142948 (2 µg/kg; chamber; single dose) inhibits NT (10 pg/mouse)-induced turning behavior [2]. |
| Animal Protocol |
Animal/Disease Models: Female Swiss albino CD1 mouse (25-30 g; striatal injection 10 pg/mouse NT)[2]./kg 53% and mouse 4mg/kg 54%)[2]. Doses: 2 µg/kg Route of Administration: Oral; single. Experimental Results: Within 1-2 hrs (hrs (hours)) after administration, the flipping behavior was inhibited and had the largest and significant antagonistic effect. |
| References |
[1]. Neurotensin type 1 receptor-mediated activation of krox24, c-fos and Elk-1: preventing effect of the neurotensin antagonists SR 48692 and SR 142948. FEBS Lett. 1998 Jul 31;432(1-2):88-93. [2]. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther. 1997 Feb;280(2):802-12. |
| Additional Infomation | 2-[[[5-(2,6-dimethoxyphenyl)-1-[4-[[3-(dimethylamino)propyl-methylamino]-oxomethyl]-2-propan-2-ylphenyl]-3-pyrazolyl]-oxomethyl]amino]-2-adamantanecarboxylic acid is a N-acyl-amino acid. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4580 mL | 7.2902 mL | 14.5804 mL | |
| 5 mM | 0.2916 mL | 1.4580 mL | 2.9161 mL | |
| 10 mM | 0.1458 mL | 0.7290 mL | 1.4580 mL |